REDAELLI, SARA
REDAELLI, SARA
DIPARTIMENTO DI MEDICINA E CHIRURGIA (SCHOOL OF MEDICINE AND SURGERY)
Expression, purification, and inhibition of human RET tyrosine kinase
2005 Mologni, L; Sala, E; Riva, B; Cesaro, L; Cazzaniga, S; Redaelli, S; Marin, O; Pasquato, N; Donella Deana, A; GAMBACORTI PASSERINI, C
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling
2006 Gunby, R; Ahmed, S; Sottocornola, R; Gasser, M; Redaelli, S; Mologni, L; Tartari, C; Belloni, V; GAMBACORTI PASSERINI, C; Scapozza, L
In vitro and in vivo activity of SKI-606, a novel Abl/Src inhibitor, against imatinib resistant BCR-ABL plus neoplastic
2006 Puttini, M; Coluccia, A; Boschelli, F; Franceschino, A; Tomaghi, L; Ahmed, S; Redaelli, S; Piazza, R; Magistroni, V; Andreoni, F; Scapozza, L; Formelli, F; GAMBACORTI PASSERINI, C
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl(+) neoplastic cells
2006 Puttini, M; Coluccia, A; Boschelli, F; Cleris, L; Marchesi, E; Donella Deana, A; Ahamed, S; Redaelli, S; Piazza, R; Magistroni, V; Andreoni, F; Scapozza, L; Formelli, F; GAMBACORTI PASSERINI, C
Inhibition of RET tyrosine kinase by SU5416
2006 Mologni, L; Sala, E; Cazzaniga, S; Rostagno, R; Kuoni, T; Puttini, M; Bain, J; Cleris, L; Redaelli, S; Riva, B; Formelli, F; Scapozza, L; GAMBACORTI PASSERINI, C
Bcr-Abl stabilizes beta-catenin in chronic myeloid leukemia through its tyrosine phosphorylation
2007 Coluccia, A; Vacca, A; Dunach, M; Mologni, L; Redaelli, S; Bustos, V; Benati, D; Pinna, L; GAMBACORTI PASSERINI, C
NPM/ALK binds and phosphorylates the RNA/DNA binding protein PSF in anaplastic large cell lymphoma
2007 Galietta, A; Gunby, R; Redaelli, S; Bachi, A; Piazza, R; Villa, A; Pogliani, E; Gambacorti Passerini, C
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma
2007 Galietta, A; Gunby, R; Redaelli, S; Stano, P; Carniti, C; Bachi, A; Tucker, P; Tartari, C; Huang, C; Colombo, E; Pulford, K; Puttini, M; Piazza, R; Ruchatz, H; Villa, A; Donella deana, A; Marin, O; Perrotti, D; GAMBACORTI PASSERINI, C
Characterization of compound 584, an Abl kinase inhibitor with lasting effects
2008 Puttini, M; Redaelli, S; Moretti, L; Brussolo, S; Gunby, R; Mologni, L; Marchesi, E; Cleris, L; Donella deana, A; Drueckes, P; Sala, E; Lucchini, V; Kubbutat, M; Formelli, F; Zambon, A; Scapozza, L; GAMBACORTI PASSERINI, C
Determination of the Activity Profile of Bosutinib, Dasatinib and Nilotinib against 18 Imatinib Resistant Bcr/Abl Mutants
2008 Redaelli, S; Piazza, R; Rostagno, R; Sassone, M; Magistroni, V; Perini, P; Marega, M; Boschelli, F; GAMBACORTI PASSERINI, C
BCR and BCR/ABL Regulation during Myeloid Differentiation in Healthy Donors and in Chronic Phase/Blast Crisis CML Patients
2008 Marega, M; Piazza, R; Meneghetti, I; Redaelli, S; Mogavero, A; GAMBACORTI PASSERINI, C
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay
2009 Piazza, R; Redaelli, S; Ceccon, M; Mogavero, A; Marega, M; Mologni, L; Boschelli, F; Pogliani, E; GAMBACORTI PASSERINI, C
Bosutinib is a Substrate of the ABC Efflux Transporter P-Glycoprotein
2009 Perini, P; Redaelli, S; Piazza, R; Viltadi, M; Boschelli, F; GAMBACORTI PASSERINI, C
BCR AND BCR-ABL REGULATION DURING MYELOID DIFFERENTIATION IN HEALTHY DONORS AND CHRONIC PHASE-BLAST CRISIS CML PATIENTS
2009 Marega, M; Piazza, R; Iacobucci, I; Meneghetti, I; Pirola, A; Redaelli, S; Mogavero, A; Parma, M; Pogliani, E; GAMBACORTI PASSERINI, C
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants
2009 Redaelli, S; Piazza, R; Rostagno, R; Magistroni, V; Perini, P; Marega, M; GAMBACORTI PASSERINI, C; Boschelli, F
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients
2010 Marega, M; Piazza, R; Pirola, A; Redaelli, S; Mogavero, A; Iacobucci, I; Meneghetti, I; Parma, M; Pogliani, E; GAMBACORTI PASSERINI, C
A New BCR-ABL1 Mutation (L248R) Is Highly Resistant to Imatinib, Bosutinib, Nilotinib and Dasatinib, but Can Be Inhibited by AP-24534 and DCC-2036
2010 Redaelli, S; Mologni, L; Rostagno, R; Piazza, R; Viltadi, M; Wise, S; Flynn, D; GAMBACORTI PASSERINI, C
Reply to P. Laneuville et al
2010 Gambacorti-Passerini, C; Piazza, R; Perini, P; Rostagno, R; Redaelli, S
Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib
2010 Redaelli, S; Boschelli, F; Perini, P; Pirola, A; Viltadi, M; GAMBACORTI PASSERINI, C
ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells
2011 Magistroni, V; Mologni, L; Sanselicio, S; Reid, J; Redaelli, S; Piazza, R; Viltadi, M; Bovo, G; Strada, G; Grasso, M; Gariboldi, M; GAMBACORTI PASSERINI, C